Skip to content

A prospective, multicenter cohort study of pan-cancer screening in Chinese population

A prospective, multicenter, noninterventional cohort study of muti-omics models for pan-cancer screening

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053705
Enrollment
Unknown
Registered
2021-11-27
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Index test:Pan-cancer&#32
early&#32
screening&#32
model&#32

Sponsors

Fudan University Taizhou Institute of Health Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 75 years (including critical value), gender is not limited; 2. Physical examination in the research center and no history of tumor; 3. Subjects who can voluntarily complete the "Population Health Tracking Survey - Simplified Questionnaire" according to the design of this research program and receive annual follow-up physical examination; 4. Agree to timely feed back the information related to tumor diagnosis in the process of visiting a doctor in a foreign hospital to the researcher during the research process; 5. Those who have no family planning in the past 3 years; 6. Those who have a full understanding of this research and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have been diagnosed with esophageal cancer, gastric cancer, colorectal cancer, liver cancer, lung cancer, pancreatic cancer, breast cancer (including non-primary, such as recurrence, metastasis or other complications) and other malignant tumors; 2. Those who have received major surgery such as blood transfusion and transplantation within 3 months; 3. Participate in other interventional clinical investigators within 3 months; 4. Pregnant or lactating women; 5. Those who suffer from autoimmune diseases, genetic diseases, mental diseases/disability and other diseases that the researchers consider unsuitable to participate in this study; 6. The compliance is poor, and it is judged by the researcher that the researcher cannot be completed.

Design outcomes

Primary

MeasureTime frame
ctDNA methylation;ctDNA mutation;cfDNA fragmentation;sensitivity, specificity, positive predictive value and negative predictive value;

Countries

China

Contacts

Public ContactChen Xingdong

Fudan University Taizhou Institute of Health Sciences

xingdongchen@fudan.edu.cn+86 13564793419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026